No price history available.
Key financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | TWDm | 270 | 242 | 318 | 333 | 537 | 485 | N/A | N/A |
| Operating profit | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | TWDm | -32 | 5 | -5 | 144 | 211 | 50 | N/A | N/A |
| EPS reported | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Jia Jie Biomedical Co., Ltd., headquartered in Kaohsiung, Taiwan, was established in 1995. Formerly known as Murad Chia Jei Biotechnology Co., Ltd. until its rebranding in June 2019, the company primarily specializes in the production and distribution of health foods and wellness products across both Taiwan and Mainland China. The company's core operations encompass the processing, sale, and trade of softshell turtle-derived food items, as well as the manufacturing of dairy products. Its diversified food portfolio also features a range of specialty items such as softshell turtle egg powder capsules, enzyme powders, tortoise jelly, softshell turtle oil, and various other encapsulated nutritional supplements. Beyond its food production, Jia Jie Biomedical engages in comprehensive import/export activities, product distribution, and managing bidding and quotation procedures for its offerings. It also operates as a wholesaler for a broad array of consumer goods, including non-alcoholic beverages, confectioneries, baked goods, dietary supplements, general groceries, everyday household items, and cosmetics. Further expanding its business scope, the company manufactures water purification systems and their associated components, provides brokerage services for life and property insurance, and invests in the research, development, and production of advanced aquatic product technologies and various biological solutions.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Jia Jie Biomedical Co., Ltd. (4109.TWO)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Jia Jie Biomedical Co., Ltd., headquartered in Kaohsiung, Taiwan, was established in 1995. Formerly known as Murad Chia Jei Biotechnology Co., Ltd. until its rebranding in June 2019, the company primarily specializes in the production and distribution of health foods and wellness products across both Taiwan and Mainland China. The company's core operations encompass the processing, sale, and trade of softshell turtle-derived food items, as well as the manufacturing of dairy products. Its diversified food portfolio also features a range of specialty items such as softshell turtle egg powder capsules, enzyme powders, tortoise jelly, softshell turtle oil, and various other encapsulated nutritional supplements. Beyond its food production, Jia Jie Biomedical engages in comprehensive import/export activities, product distribution, and managing bidding and quotation procedures for its offerings. It also operates as a wholesaler for a broad array of consumer goods, including non-alcoholic beverages, confectioneries, baked goods, dietary supplements, general groceries, everyday household items, and cosmetics. Further expanding its business scope, the company manufactures water purification systems and their associated components, provides brokerage services for life and property insurance, and invests in the research, development, and production of advanced aquatic product technologies and various biological solutions.
